IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

atent Application of James A. Audia et al.

Group Art Unit:

1625

Application No.: 10/768,970

Examiner:

Filing Date:

February 2, 2004

Confirmation No.: 4567

SYNTHESIS

FIRST REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Title: METHODS AND COMPOUNDS FOR INHIBITING B-AMYLOID PEPTIDE RELEASE AND/OR ITS

Commissioner for Patents Office of Initial Patent Examination **Customer Service Center** P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Enclosed is a copy of the Official Filing Receipt marked in red to show correction/corrections that is/are needed. The correction/corrections is/are as follows:

After the second line of domestic priority data please insert the following: which claims priority from applications Serial Nos. 60/064,859; 60/108/161; and 60/098,558, all filed February 28, 1997;

Additionally, after the last line of domestic priority data, please insert the following: and from Serial No. 60/064,859, filed February 28, 1997.

Issuance of a corrected Official Filing Receipt is respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: June 2, 2019

Brian A O'Shaughness

Registration No. 32,74



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. BOX 1450 Alexandria, Virginia 22313-1450

FILING OR 371 (c) DATE APPL NO. **ART UNIT FIL FEE REC'D** ATTY.DOCKET NO DRAWINGS TOT CLMS IND CLMS 10/768,970 02/02/2004 1625 0.00

034074-794

CONFIRMATION NO. 4567

Date Mailed: 05/12/2004

FILING RECEIPT

OC000000012604147

21839 BURNS DOANE SWECKER & MATHIS L L P POST OFFICE BOX 1404 **ALEXANDRIA, VA 22313-1404**

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

James E. Audia, Indianapolis, IN; Thomas C. Britton, Carmel, IN; James J. Droste, Indianapolis, IN; Beverly K. Folmer, Newark, DE: George W. Huffman, Carmel, IN; Varghese John, San Francisco, CA; Lee H. Latimer, Oakland, CA; Thomas E. Mabry, Indianapolis, IN; Jeffrey S. Nissen, Indianapolis, IN; Warren J. Porter, Indianapolis, IN; Jon K. Reel, Carmel, IN; Eugene D. Thorsett, Moss Beach, CA: Jay S. Tung, Belmont, CA; Jing Wu, San Mateo, CA; Clark Norman Eid, Cheshire, CT: William Leonard Scott, Indianapolis, IN:

Assignment For Published Patent Application


Elan Pharmaceuticals, Inc., South San Francisco, CA; Eli Lilly & Company, Indianapolis, IN;

Domestic Priority data as claimed by applicant

This application is a CON of 10/309,569 12/03/2002 which is a CON of 09/789,487, 02/20/2001

and is a CON of 08/976,289 11/21/1997 PAT 6,191,166 which claims benefit of 60/108,166 11/22/1996 ABN and from Serial No. 60/064,859, filed Feb. 28, 1997

which claims priority from applications Serial Nos. 60/064,859; 60/108, 161; and 60/048,558, all filed Feb. 28, 1997;



and claims benefit of 60/064,859 02/28/1997 ABN

Foreign Applications

If Required, Foreign Filing License Granted: 05/11/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis

Preliminary Class

514

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

J (*)